Bio-Process Systems Alliance Announces 2025/2026 Board Slate
December 10, 2024
December 10, 2024
Arlington, VA– The Bio-Process Systems Alliance (BPSA), the international association for the single-use bioprocessing industry, has announced its newly elected Board members for 2025–2026, following the December 5th Board meeting.
Mark Petrich, PhD, Vice President, Process Development & Validation, Krystal Biotech, Inc., was re-elected as Chair for a second two-year term, and Todd Kapp, CEO of Business Development at Wautoma Biotech LLC, was re-elected as First Vice Chair.
Brendan Lucey, Cross Business Unit Director of Marketing Strategy-Life Sciences, Entegris, Inc., and Ping Wang, PhD, Director, Material Sciences, Therapeutics Development & Supply (TDS), Discovery, Product Development & Supply, Johnson & Johnson Innovative Medicine, were elected to two-year terms as Directors at-large.
Lucey oversees the go-to-market strategy for Life Sciences at Entegris. He has previously served on the BPSA Board and currently chairs the BPSA Cell and Gene Therapy Committee. A biologist by training, he previously held positions at CDMOd, Lonza, Sartorius, ILC Dover and Gemini Bio.
Wang serves as a Scientific Director at Johnson & Johnson Innovative Medicine, responsible for the selection, qualification and investigation of single-use materials used for the J&J large molecules R&D and manufacturing network. Within BPSA, Ping is actively engaged in the BPSA Cell & Gene Therapy, End-user Committee and X-ray Sterilization Committees. Ping earned a PhD from the College of Pharmacy at University of Georgia, an MBA from Drexel University, and MS and BS degrees from Peking University.
Patrick Evrard, Quality Assurance/Regulatory Affairs, Cytiva; Charlott Masy, PhD, Senior Manager, GSK; Ralph Daumke, Market Manager EMEA, PendoTECH; Hernán Parma, Head of Sales-America, RENOLIT Healthcare and Stuart Tindal, EngD., PhD, Product Manager, Sartorius, were also re-elected as Directors-at-Large for two-year (2025-2026) terms.
“I extend my congratulations to Mark and Todd on their re-election as Chair and First Vice Chair,” said BPSA Executive Director Chris Clark. “As BPSA enters its 20th year, their extensive experience and leadership will be critical in guiding the Alliance as we move forward. I also congratulate our new and returning Board members and thank all our dedicated volunteer leaders for their time, expertise, and commitment to advancing BPSA’s mission.” Clark added, “A special thanks to Matt Sitcoske of High Purity New England and Danielle Arcuri of Qosina Corporation for their invaluable contributions as Directors-at-Large as their terms conclude this year.”
BPSA Executive Board Officers:
At-Large Directors (newly elected) through 2026:
At-Large Directors continuing through 2025 and/or 2026:
Board members are elected by BPSA’s general membership to serve staggered two-year terms. They establish governing policies, determine budget priorities, and set strategic goals to advance the organization and its mission of supporting the single-use bioprocessing industry globally.
Please visit https://bpsalliance.org/about/board-of-directors/ for a complete list of BPSA Board of Directors.
About BPSA
An affiliate of SOCMA, the Bio-Process Systems Alliance, is an industry-led association dedicated to encouraging and accelerating the adoption of single-use manufacturing technologies used in the production of biopharmaceuticals and vaccines. BPSA facilitates education, best practice sharing, development of consensus guides and networking opportunities among its member companies. For more information, visit www.bpsalliance.org.